Different diuretic dose and response in acute decompensated heart failure: Clinical characteristics and prognostic significance

被引:23
|
作者
Palazzuoli, Alberto [1 ]
Testani, Jeffrey M. [2 ]
Ruocco, Gaetano [1 ]
Pellegrini, Marco [1 ]
Ronco, Claudio [3 ]
Nuti, Ranuccio [1 ]
机构
[1] Univ Siena, S Maria Alle Scotte Hosp, Cardiovasc Dis Unit, Dept Internal Med, Siena, Italy
[2] Yale Univ, Sch Med, Dept Internal Med, Program Appl Translat Res, New Haven, CT 06510 USA
[3] St Bortolo Hosp, Nephrol Dialysis & Transplantat, Int Renal Res Inst IRRIV, Vicenza, Italy
关键词
Acute heart failure; Loop diuretics; Worsening renal function; Diuretic efficiency; Outcome; WORSENING RENAL-FUNCTION; LOOP DIURETICS; AN ANALYSIS; CONGESTION; OUTCOMES; HOSPITALIZATION; RELIEF; MORTALITY; KIDNEY; TRIAL;
D O I
10.1016/j.ijcard.2016.09.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The question regarding the correct balance between optimal loop diuretic dose administration and best modality is under debate as well as the exact relation existing between congestion and renal dysfunction. We sought to evaluate the effects of different diuretic modalities (low [LD] versus high dose [HD]) and dose administration on decongestion, Worsening renal function (WRF) and outcome. Methods: We retrospectively analyzed data of DIUR-HF study matching for LD vs HD (cut off 125 mg/day), and diuretic efficiency (DE) (weight loss/40mgdaily of furosemide). We also evaluated WRF rate (creatinine increase during hospitalization >= 0.3 mg/dl or estimated glomerular filtration rate (eGFR) reduction >= 25%) together with decongestion. Results: HD patients (n.55) were older, more frequently affected by diabetes and chronic kidney disease (CKD) and demonstrated higher rate of inhospital WRF (65% vs 29% p = 0.001) and 180-days adverse events (70% vs 23% p < 0.001) respect to LD patients (n.41). Patients with low DE showed a higher 180 days adverse events rate than higher DE patients (p=0.02). Univariate and multivariable analysis suggests a significant relationship between adverse events and low DE (patients with DE under median value) (U-HR = 2.59 [1.44-4.64]; p = 0.001. M-HR = 3.16 [1.55-6.46]; p = 0.002); continuous administration (HR = 3.12 [1.65-5.91]; p < 0.001) and WRF (HR = 5.30 [2.79-10.09]; p < 0.001) were also related with adverse events. Conclusions: HD and poor DE are two conditions associated with adverse outcome. Both situations are the consequence of previous detrimental clinical status and they appear strictly related to WRF occurrence. (C) 2016 Published by Elsevier Ireland Ltd.
引用
收藏
页码:213 / 219
页数:7
相关论文
共 50 条
  • [31] Clinical Significance of Systemic Vascular Resistance in Acute Decompensated Heart Failure
    Mizutani, Tomohiro
    Inomata, Takayuki
    Yanagisawa, Tomoyoshi
    Maekawa, Emi
    Naruke, Takashi
    Takeuchi, Ichirou
    Izumi, Toru
    [J]. JOURNAL OF CARDIAC FAILURE, 2009, 15 (07) : S172 - S172
  • [32] Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure
    Ikeda, Shuntaro
    Ohshima, Kiyotaka
    Miyazaki, Shigehiro
    Kadota, Hisaki
    Shimizu, Hideaki
    Ogimoto, Akiyoshi
    Hamada, Mareomi
    [J]. ESC HEART FAILURE, 2017, 4 (04): : 614 - 622
  • [33] Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review
    Laura Leto
    Nadia Aspromonte
    Mauro Feola
    [J]. Heart Failure Reviews, 2014, 19 : 237 - 246
  • [34] Discharge Diuretic Dose and 30-Day Readmission Rate in Acute Decompensated Heart Failure
    Woodruff, Ashley E.
    Kelley, Ashley M.
    Hempel, Carolyn A.
    Loeffler, William J.
    Echtenkamp, Christine A.
    Hassan, Amany K.
    [J]. ANNALS OF PHARMACOTHERAPY, 2016, 50 (06) : 437 - 445
  • [35] Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review
    Leto, Laura
    Aspromonte, Nadia
    Feola, Mauro
    [J]. HEART FAILURE REVIEWS, 2014, 19 (02) : 237 - 246
  • [36] Safety and Efficacy of High Dose Spironolactone in Loop Diuretic Resistant Acute Decompensated Heart Failure
    Velagapudi, Chakradhar
    Bansal, Shweta
    Munoz, Kristina
    Brune, Sonja
    Prasad, Anand
    [J]. CIRCULATION, 2018, 138
  • [37] Usefulness of in-hospital loop diuretic amount and diuretic response measurements in patients with acute decompensated heart failure
    Ruocco, G.
    Evangelista, I.
    Nuti, R.
    Palazzuoli, A.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 538 - 538
  • [38] The prognostic implications of outpatient diuretic dose in heart failure
    Harjai, KJ
    Dinshaw, HK
    Nunez, E
    Shah, M
    Thompson, H
    Turgut, T
    Ventura, HO
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 1999, 71 (03) : 219 - 225
  • [39] Prognostic Implications of Diuretic Dose in Chronic Heart Failure
    Martins, Joao
    Lourenco, Patricia
    Araujo, Jose Paulo
    Mascarenhas, Joana
    Lopes, Ricardo
    Azevedo, Ana
    Bettencourt, Paulo
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2011, 16 (02) : 185 - 191
  • [40] DOES OBESITY AFFECT RESPONSE TO TREATMENT IN ACUTE DECOMPENSATED HEART FAILURE? A DIURETIC OPTIMIZATION STRATEGIES EVALUATION (DOSE) TRIAL SUBSTUDY
    Gupta, Achal
    Stehlik, Josef
    McNulty, Steven
    Lee, Kerry L.
    Gilbert, Edward M.
    Budge, Deborah
    Anstrom, Kevin
    Bull, David A.
    Felker, G. Michael
    Verma, Divya R.
    Drakos, Stavros G.
    Owan, Theophilus
    O'Connor, Christopher M.
    Litwin, Sheldon E.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E199 - E199